The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; Agenus; Agios; Astellas Pharma; AstraZeneca; Black Diamond Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-MAB; Immunome; IQvia; Macrogenics; Pfizer; QED Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; Sotio; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Mary Josephine Paula Pilat
No Relationships to Disclose
 
Cesar Augusto Santa-Maria
Consulting or Advisory Role - Athenex; Bristol-Myers Squibb; Genomic Health; Halozyme; Polyphor
Research Funding - Medimmune; Pfizer; Pfizer; Tesaro (Inst)
 
Roisin M. Connolly
Research Funding - Genentech/Roche (Inst); Macrogenics (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Erin Elizabeth Roesch
Honoraria - Puma Biotechnology
Speakers' Bureau - Puma Biotechnology
 
Anosheh Afghahi
No Relationships to Disclose
 
Hyo S. Han
Consulting or Advisory Role - Pfizer
Speakers' Bureau - Lilly; Lilly
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Horizon Oncology Research (Inst); Novartis (Inst); Pfizer (Inst); Prescient Therapeutics (Inst); Seagen (Inst); TapImmune Inc. (Inst); Tesaro (Inst)
 
Rita Nanda
Consulting or Advisory Role - Aduro Biotech; Athenex; Daiichi Sankyo; Genentech/Roche; ION Pharma; Macrogenics; Merck; Pfizer; Seagen
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Other Relationship - G1 Therapeutics
 
Gerburg M. Wulf
Stock and Other Ownership Interests - Selecta Biosciences (I)
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - Pin1 as a marker for abnormal cell growth Patent number: 8129131
 
Hadeel Assad
Consulting or Advisory Role - Daiichi Sankyo
 
Haeseong Park
Research Funding - Ambrx (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Oncologie (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Turning Point Therapeutics (Inst); Vertex (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bayer
 
Elizabeth Claire Dees
Consulting or Advisory Role - G1 Therapeutics; Novartis (I); Strata Oncology
Research Funding - Bayer; Cerulean Pharma; Genentech/Roche; H3 Biomedicine; Lilly; Merck; Meryx Pharmaceuticals; Novartis; Pfizer
Travel, Accommodations, Expenses - G1 Therapeutics
 
Jeremy Meyer Force
Consulting or Advisory Role - Myriad Genetics; NanoString Technologies; Pfizer
Speakers' Bureau - Genomic Health
 
Anne M. Noonan
Consulting or Advisory Role - Exelixis; Helsinn Healthcare; QED Therapeutics
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Bayer; Bioarray Therapeutics; bioTheranostics; Celgene; Eisai; Genentech/Roche; Genomic Health; Lilly; Merck; Myriad Pharmaceuticals; NanoString Technologies; Novartis; Pfizer; Puma Biotechnology
 
Vandana G Abramson
Employment - HCA Healthcare (I)
Consulting or Advisory Role - Abbvie; Daiichi Sankyo; Eisai
Research Funding - Astellas Pharma; Genentech/Roche; Lilly
 
Barbara B. Haley
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst)
 
Saundra S. Buys
No Relationships to Disclose
 
Elad Sharon
No Relationships to Disclose
 
Kurt A. Schalper
Consulting or Advisory Role - Abbvie; Agenus; AstraZeneca; Celgene; Clinica Alemana; Dynamo Therapeutics; EMD Serono; Moderna Therapeutics; Pierre Fabre; Shattuck Labs; Torque
Speakers' Bureau - Bristol-Myers Squibb; Fluidigm; Merck
Research Funding - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; Moderna Therapeutics; Navigate BioPharma; Pierre Fabre; Surface Oncology; Takeda; Tesaro
Patents, Royalties, Other Intellectual Property - Patent No. 16/464,010 (PREDICTION OF RESPONSE TO IMMUNE-MODULATORY THERAPIES)